Company Profile

Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Companyâ€™s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkinâ€™s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

Employees

Sector

Pharmaceuticals

More about the company

Delayed OTC Markets 11:53:32 2026-07-02 am EDT			5-day change	1st Jan Change
1.690 ^USD	+0.90%		-.--%	+14.19%

Jul. 02	Hanmi Pharmaceutical Closes Acquisition of Aptose Biosciences	MT
Jun. 29	Hanmi Pharm. Co., Ltd. completed the acquisition of remaining 80.07% stake in Aptose Biosciences Inc..	CI

Markets		Quality
OTC Markets	APTO	Delayed
Börse Stuttgart	LTI0	Delayed

Jul. 02	Hanmi Pharmaceutical Closes Acquisition of Aptose Biosciences	MT
Jun. 29	Hanmi Pharm. Co., Ltd. completed the acquisition of remaining 80.07% stake in Aptose Biosciences Inc..	CI
Jun. 15	Aptose Biosciences Inc. Presents Safety, Response and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML	CI
Jun. 15	Aptose Biosciences Updated Tuscany Trial Data Reported in Oral Presentation at EHA 2026	MT
May. 29	Aptose Biosciences Says Acquisition by Hanmi Delayed Until June	MT
May. 29	Aptose Biosciences says closing of arrangement with Hanmi Pharmaceutical further delayed	RE
May. 13	Aptose Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Mar. 31	Aptose Shareholders Approve Acquisition By Hanmi Pharmaceutical in "Go Private" Transaction	MT
Mar. 31	Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 31	Aptose Biosciences Inc. - Shareholder/Analyst Call
Mar. 30	Aptose Biosciences Inc. Auditor Raises 'Going Concern' Doubt	CI
Mar. 23	Leading independent proxy advisory firm Glass Lewis endorses Aptose plan of arrangement	RE
Mar. 23	Aptose Biosciences Brief: Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement With Hanmi Pharmaceutical	MT

Mar. 19	Leading independent proxy advisory firm ISS recommends Aptose Biosciences shareholders vote "for" proposed plan of arrangement with Hanmi Pharmaceutical	RE
Mar. 19	Aptose Brief: Independent Proxy Advisory Firm ISS Recommends Aptose Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical	MT
24-06-11	HC Wainwright Adjusts Price Target on Aptose Biosciences to $7 From $23, Maintains Buy Rating	MT
23-11-10	RBC Cuts Price Target on Aptose Biosciences to $18 From $23, Keeps Outperform, Speculative Risk	MT
23-08-11	Oppenheimer Adjusts Aptose Biosciences Price Target to $15 From $50, Maintains Outperform Rating	MT

Aptose Biosciences Inc. Stock OTC Markets

Stocks

APTO

CA03835T4081

Pharmaceuticals

Chart: Aptose Biosciences Inc.

Latest news: Aptose Biosciences Inc.

Last Transcript: Aptose Biosciences Inc.

Analysts' recommendations: Aptose Biosciences Inc.

Press Releases: Aptose Biosciences Inc.

News in other languages: Aptose Biosciences Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Aptose Biosciences Inc.

Other Pharmaceuticals

Company Profile

Jun. 30	Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical	AQ
Jun. 15	Aptose Biosciences : Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	PU
Jun. 15	Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	AQ
May. 29	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical	AQ
May. 13	Aptose Biosciences: Q1 Earnings Snapshot	AQ

Dec. 05	Tokenización: ¿Va a cambiar tanto la vida de los inversores?
Dec. 05	Universo cripto: la tokenizzazione cambierà davvero la vita degli investitori?
23-09-09	Vastzetting: Ethereum scheert hoge toppen - cryptonieuws
23-09-08	Staking: Ethereum raggiunge nuove vette - Resoconto Cripto

Current year	1.24	1.74
1 year	1.08	1.74
3 years	0.64	99.6
5 years	0.64	1,251
10 years	0.64	4,163.63

Manager	Title	Age	Since
C. Payne DFI	Director of Finance/CFO	63	2022-06-26
Victor Montalvo-Lugo CTO	Chief Tech/Sci/R&D Officer	-	2019-10-31
Rafael Bejar CTO	Chief Tech/Sci/R&D Officer	54	2019-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOSE BIOSCIENCES INC.	+0.90%	-.--%	-	-	4.32M
ELI LILLY AND COMPANY	-0.72%	+0.28%	+61.51%	+118.45%	1,056B
JOHNSON & JOHNSON	-1.71%	-0.82%	+47.01%	+71.43%	655B
ABBVIE INC.	-0.91%	-0.64%	+18.09%	+76.79%	471B
ROCHE HOLDING AG	-1.74%	-4.09%	+36.35%	+39.43%	342B
NOVARTIS AG	-0.39%	+3.83%	+22.08%	+28.82%	277B
ASTRAZENECA PLC	-0.54%	-2.10%	+11.89%	+11.75%	257B
AMGEN INC.	-0.14%	+1.41%	+51.85%	+54.79%	226B
GILEAD SCIENCES, INC.	-1.93%	-2.38%	+32.33%	+98.87%	189B
NOVO NORDISK A/S	-0.24%	-2.76%	-28.41%	-60.92%	170B
Average	-0.74%	+0.97%	+28.08%	+48.82%	404.77B
Weighted average by Cap.	-0.98%	+1.04%	+38.13%	+69.52%

1 day	+0.90%
3 months	+9.03%
6 months	+4.86%
Current year	+14.19%